The role of T cell immunity in HIV-1 infection

Current Opinion in Virology

Volumn 3, Issue 4, 2013, Pages 438-446

  Mee Ling Munier, C ^a   Kelleher, Anthony D ^a,b   Kent, Stephen J ^c   De Rose, Robert ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; TH17 CELL; VACCINATION; VIRUS REPLICATION;

EID: 84885083909     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.05.009     Document Type: Review

References (98)

1. Geskus RB, Prins M, Hubert JB, Miedema F, Berkhout B, Rouzioux C, Delfraissy JF, Meyer L: The HIV RNA setpoint theory revisited. Retrovirology 2007, 4:65.
2. Balamurali M, Petravic J, Loh L, Alcantara S, Kent SJ, Davenport MP: Does cytolysis by CD8+ T cells drive immune escape in HIV infection? J Immunol 2010, 185:5093-5101.
3. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG et al.: The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009, 206:1253-1272.
4. Schneidewind A, Brumme ZL, Brumme CJ, Power KA, Reyor LL, O'Sullivan K, Gladden A, Hempel U, Kuntzen T, Wang YE et al.: Transmission and long-term stability of compensated CD8 escape mutations. J Virol 2009, 83:3993-3997.
5. Brenchley JM, Ruff LE, Casazza JP, Koup RA, Price DA, Douek DC: Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol 2006, 80:6801-6809. (Pubitemid 44025180)
6. Ferrando-Martinez S, Ruiz-Mateos E, Romero-Sanchez MC, Munoz-Fernandez MA, Viciana P, Genebat M, Leal M: HIV infection-related premature immunosenescence: high rates of immune exhaustion after short time of infection. Curr HIV Res 2011, 9:289-294.
7. Khaitan A, Unutmaz D: Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 2011, 8:4-11.
8. Prendergast A, Goodliffe H, Clapson M, Cross R, Tudor- Williams G, Riddell A, Daniels J, Williams A, Goulder P: Gagspecific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection. AIDS 2011, 25:1329-1331.
9. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD: Long-term HIV-1 infection without immunologic progression. AIDS 1994, 8:1123-1128. (Pubitemid 24228710)
10. Deeks SG, Walker BD: Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416. (Pubitemid 47418678)
11. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, Kaufmann DE, Trocha A, Block BL et al.: Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 2010, 84:7581-7591.
12. Tang J, Cormier E, Gilmour J, Price MA, Prentice HA, Song W, Kamali A, Karita E, Lakhi S, Sanders EJ et al.: Human leukocyte antigen variants B44 and B57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub- Saharan Africans with several viral subtypes. J Virol 2011, 85:8894-8902.
13. Prentice HA, Porter TR, Price MA, Cormier E, He D, Farmer PK, Kamali A, Karita E, Lakhi S, Sanders EJ et al.: HLA-B57 versus HLA-B81 in HIV-1 infection: slow and steady wins the race? J Virol 2013, 87:4043-4051.
14. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, Wang B, Losina E, Miura T, Chonco F et al.: Gagprotease- mediated replication capacity in HIV-1 subtype C chronic infection: Associations with HLA type and clinical parameters. J Virol 2010, 84:10820-10831.
15. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, Kadie CM, Carlson JM, Markle TJ, Streeck H et al.: Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol 2010, 84:11937-11949.
16. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, Deeks SG, Pereyra F, Carrington M, Walker BD, Chakraborty AK: Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010, 465:350-354. This article provided a framework for HLA-*B57-mediated control of HIV replication by defining how the peptide-binding characteristics of this molecule during thymic selection select for a larger repertoire of HLA- *B57 clones with broader specificity for HIV sequences that are more refractive for mutational escape by HIV.
17. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, Workman C, Shaunak S, Olson K, Goulder P et al.: Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001, 193:375-386.
18. Brennan CA, Ibarrondo FJ, Sugar CA, Hausner MA, Shih R, Ng HL, Detels R, Margolick JB, Rinaldo CR, Phair J et al.: Early HLAB 57-restricted CD8+ T lymphocyte responses predict HIV-1 disease progression. J Virol 2012, 86:10505-10516.
19. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M et al.: The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557. The authors demonstrated that a small number of amino acids that flank the binding grove in HLA molecules are the major genetic determinants for HIV control or susceptibility.
20. Carrington M, O'Brien SJ: The influence of HLA genotype on AIDS. Annu Rev Med 2003, 54:535-551. (Pubitemid 37386411)
21. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Altfeld M, O'Brien SJ, Carrington M: AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005, 11:1290-1292. (Pubitemid 41752907)
22. Matthews PC, Koyanagi M, Kloverpris HN, Harndahl M, Stryhn A, Akahoshi T, Gatanaga H, Oka S, Juarez Molina C, Valenzuela Ponce H et al.: Differential clade-specific HLA-B3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope. J Virol 2012, 86:12643-12654.
23. Huber M, Trkola A: Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007, 262:5-25. (Pubitemid 47000630)
24. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB: Virusspecific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110. (Pubitemid 24258634)
25. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655. (Pubitemid 24183063)
26. Wilson JD, Ogg GS, Allen RL, Davis C, Shaunak S, Downie J, Dyer W, Workman C, Sullivan S, McMichael AJ, Rowland- Jones SL: Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 2000, 14:225-233. (Pubitemid 30132915)
27. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L et al.: Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998. (Pubitemid 29149355)
28. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, Bangham CR, Phillips RE: Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997, 94:1890-1895. (Pubitemid 27113932)
29. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, Wong K, McLaughlin S, McSweyn MD, Diem K, Stevens CE et al.: Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 2006, 80:9519-9529. (Pubitemid 44435628)
30. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M et al.: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789. (Pubitemid 43882629)
31. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E et al.: Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008, 197:563-571. (Pubitemid 351321534)
32. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M et al.: HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002, 3:1061-1068. (Pubitemid 35363659)
33. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barre-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A: HIV controllers exhibit potent CD8T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007, 104:6776-6781. (Pubitemid 47175577)
34. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, Kovacs CM, Rodriguez B, Sieg SF, Teixeira-Johnson L et al.: Perforin expression directly ex vivo by HIV-specific CD8 Tcells is a correlate of HIV elite control. PLoS Pathog 2010, 6:e1000917.
35. Hersperger AR, Martin JN, Shin LY, Sheth PM, Kovacs CM, Cosma GL, Makedonas G, Pereyra F, Walker BD, Kaul R et al.: Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood 2011, 117:3799-3808. This study reveals that HIV-specific CD8 T cells from elite controllers express higher levels of the transcription factor T-bet. A positive correlation was observed between T-bet expression and both perforin and Granzyme B expression levels.
36. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB, Yee HFJ, Martin JN, Deeks SG, Shacklett BL: Mucosal immune responses to HIV-1 in elite controllers: A potential correlate of immune control. Blood 2009, 113:3978-3989.
37. Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HFJ, Martin JN, Deeks SG, Shacklett BL: Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gagspecific responses dominate in rectal mucosa of HIV controllers. J Virol 2010, 84:10354-10365.
38. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, Addo MM, Brumme C, Routy JP, Little S et al.: Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009, 83:7641-7648.
39. Ribeiro-dos-Santos P, Turnbull EL, Monteiro M, Legrand A, Conrod K, Baalwa J, Pellegrino P, Shaw GM, Williams I, Borrow P, Rocha B: Chronic HIV infection affects the expression of the 2 transcription factors required for CD8 T-cell differentiation into cytolytic effectors. Blood 2012, 119:4928-4938.
40. Intlekofer AM, Banerjee A, Takemoto N, Gordon SM, Dejong CS, Shin H, Hunter CA, Wherry EJ, Lindsten T, Reiner SL: Anomalous type 17 response to viral infection by CD8+ T cells lacking Tbet and eomesodermin. Science 2008, 321:408-411. (Pubitemid 352029977)
41. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354. (Pubitemid 44435155)
42. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted CD8T cells during chronic viral infection. Nature 2006, 439:682-687. (Pubitemid 43237609)
43. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC, Koup RA: PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203:2281-2292. (Pubitemid 44498363)
44. Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, Jesneck JL, Brosnahan K, Imam S et al.: Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010, 16:1147-1151. Described the cellular mechanism by which the inhibitory marker PD-1 contributes to CD8 T cell exhaustion by transcriptional activation of the T cell inhibiting gene, BATF. BATF and related genes were therefore identified as potential new targets for therapy.
45. Ortiz AM, Klatt NR, Li B, Yi Y, Tabb B, Hao XP, Sternberg L, Lawson B, Carnathan PM, Cramer EM et al.: Depletion of CD4(+) T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin Invest 2011, 121:4433-4445.
46. Porichis F, Kaufmann DE: HIV-specific CD4T cells and immune control of viral replication. Curr Opin HIV AIDS 2011, 6:174-180.
47. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J, Lian J, Muller MI et al.: HIV-1- specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol 2011, 85:733-741.
48. Iannello A, Boulassel MR, Samarani S, Debbeche O, Tremblay C, Toma E, Routy JP, Ahmad A: Dynamics and consequences of IL-21 production in HIV-infected individuals: A longitudinal and cross-sectional study. J Immunol 2010, 184:114-126.
49. Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, Yee HFJ, Martin JN, Deeks SG, Shacklett BL: HIV controllers with HLA-DRB113 and HLA-DQB106 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol 2010, 84:11020-11029.
50. Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, Pavlik DF, Rodriguez-Garcia M, Pereyra F, Freeman GJ et al.: Responsiveness of HIV-specific CD4T cells to PD-1 blockade. Blood 2011, 118:965-974.
51. D'Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A, Wilson CC, Connick E, Palmer BE: Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007, 179:1979-1987.
52. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A et al.: Upregulation of CTLA-4 by HIVspecific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007, 8:1246-1254. (Pubitemid 350011764)
53. Martins G, Calame K: Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 2008, 26:133-169. (Pubitemid 351600373)
54. Thiele S, Wittmann J, Jack HM, Pahl A: miR-9 enhances IL-2 production in activated human CD4(+) T cells by repressing Blimp-1. Eur J Immunol 2012, 42:2100-2108.
55. Seddiki N, Phetsouphanh C, Swaminathan S, Xu Y, Rao S, Li J, Sutcliffe EL, Denyer G, Finlayson R, Gelgor L et al.: The microRNA-9/B-lymphocyte-induced maturation protein-1/IL- 2 axis is differentially regulated in progressive HIV infection. Eur J Immunol 2013, 43:510-520.
56. Thaventhiran JE, Fearon DT: Control of HIV infection: escape from the shadow of Blimp-1. Eur J Immunol 2013, 43:323-326.
57. Swaminathan S, Suzuki K, Seddiki N, Kaplan W, Cowley MJ, Hood CL, Clancy JL, Murray DD, Mendez C, Gelgor L et al.: Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression. J Immunol 2012, 188:6238-6246.
58. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, Ranasinghe S, Lindqvist M, Davis I, Lane K et al.: HIVspecific cytolytic CD4T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 2012, 4:123ra25.
59. Ritchie AJ, Campion SL, Kopycinski J, Moodie Z, Wang ZM, Pandya K, Moore S, Liu MK, Brackenridge S, Kuldanek K et al.: Differences in HIV-specific T cell responses between HIVexposed and -unexposed HIV-seronegative individuals. J Virol 2011, 85:3507-3516.
60. Chevalier MF, Weiss L: The split personality of regulatory T cells in HIV infection. Blood 2013, 121:29-37.
61. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, Norris PJ, Busch MP, Martin JN, Brooks C et al.: A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS ONE 2011, 6:e15924.
62. Loke P, Favre D, Hunt PW, Leung JM, Kanwar B, Martin JN, Deeks SG, McCune JM: Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood 2010, 115:e20-e32.
63. Schulze Zur Wiesch J, Thomssen A, Hartjen P, Toth I, Lehmann C, Meyer-Olson D, Colberg K, Frerk S, Babikir D, Schmiedel S et al.: Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 2011, 85:1287-1297.
64. Presicce P, Orsborn K, King E, Pratt J, Fichtenbaum CJ, Chougnet CA: Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy. PLoS ONE 2011, 6:e28118.
65. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F et al.: Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361:1548-1559.
66. Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B, Benecke A, Rogge L, Levy Y: In vivo expansion of naive and activated CD4+ CD25+ FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci USA 2010, 107:10632-10637.
67. Seddiki N, Kelleher AD: Regulatory T cells in HIV infection: who's suppressing what? Curr HIV/AIDS Rep 2008, 5:20-26. (Pubitemid 351480777)
68. Angin M, King M, Altfeld M, Walker BD, Wucherpfennig KW, Addo MM: Identification of HIV-1-specific regulatory T-cells using HLA class II tetramers. AIDS 2012, 26:2112-2115.
69. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, McElrath MJ, Horton H: Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med 2011, 17:989-995.
70. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'Acqua ML et al.: Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232. (Pubitemid 47281420)
71. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A, Hue S, Seddiki N, Hulin A, Delaneau O et al.: CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011, 7:e1002110.
72. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA: Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 2011, 117:5372-5380.
73. Crotty S: Follicular helper CD4T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
74. King C: New insights into the differentiation and function of T follicular helper cells. Nat Rev Immunol 2009, 9:757-766.
75. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F: Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 2012, 188:3247-3256.
76. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, Flanders MD, Cutler S, Yudanin N, Muller MI et al.: Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012, 122:3271-3280.
77. Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, Ambrozak DR, Sandler NG, Timmer KJ, Sun X et al.: CD4T follicular helper cell dynamics during SIV infection. J Clin Invest 2012, 122:3281-3294.
78. Xu Y, Weatherall C, Bailey M, Alcantara S, De Rose R, Estaquier J, Wilson K, Suzuki K, Corbeil J, Cooper DA et al.: Simian immunodeficiency virus infects follicular helper CD4T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol 2013, 87:3760-3773.
79. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B: CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000, 192:1553-1562.
80. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, De Leval L, Graziosi C, Pantaleo G: Follicular helper T cells serve as the major CD4T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013, 210:143-156.
81. Brenchley JM, Vinton C, Tabb B, Hao XP, Connick E, Paiardini M, Lifson JD, Silvestri G, Estes JD: Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguishprogressive and nonprogressive lentiviral infections. Blood 2012, 120:4172-4181.
82. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009, 15:893-900.
83. Cubas RA, Mudd JC, Savoye AL, Perreau M, van Grevenynghe J, Metcalf T, Connick E, Meditz A, Freeman GJ, Abesada-Terk GJ et al.: Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013, 19:494-499.
84. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, Manku H, Vyse TJ, Roncador G, Huttley GA et al.: Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010, 62:234-244.
85. Pallikkuth S, Parmigiani A, Silva SY, George VK, Fischl M, Pahwa R, Pahwa S: Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccine. Blood 2012, 120:985-993.
86. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, Foucat E, Dullaers M, Oh S, Sabzghabaei N et al.: Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011, 34:108-121.
87. Bettelli E, Korn T, Oukka M, Kuchroo VK: Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057. (Pubitemid 351871737)
88. Dandekar S, George MD, Baumler AJ: Th17 cells, HIV and the gut mucosal barrier. Curr Opin HIV AIDS 2010, 5:173-178.
89. McKinnon LR, Nyanga B, Chege D, Izulla P, Kimani M, Huibner S, Gelmon L, Block KE, Cicala C, Anzala AO et al.: Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol 2011, 187:6032-6042.
90. Micci L, Cervasi B, Ende ZS, Iriele RI, Reyes-Aviles E, Vinton C, Else J, Silvestri G, Ansari AA, Villinger F et al.: Paucity of IL-21- producing CD4(+) T cells is associated with Th17 cell depletion in SIV infection of rhesus macaques. Blood 2012, 120:3925- 3935.
91. Ciccone EJ, Greenwald JH, Lee PI, Biancotto A, Read SW, Yao MA, Hodge JN, Thompson WL, Kovacs SB, Chairez CL et al.: CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. J Virol 2011, 85:5880-5888.
92. Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said EA, Fonseca S, Wacleche V, El-Far M, Boulassel MR, Routy JP et al.: Peripheral blood CCR4+ CCR6+ and CXCR3+ CCR6+ CD4+T cells are highly permissive to HIV-1 infection. J Immunol 2010, 184:1604-1616.
93. Hartigan-O'Connor DJ, Abel K, Van Rompay KK, Kanwar B, McCune JM: SIV replication in the infected rhesus macaque is limited by the size of the preexisting TH17 cell compartment. Sci Transl Med 2012, 4:136ra69.
94. Brandt L, Benfield T, Mens H, Clausen LN, Katzenstein TL, Fomsgaard A, Karlsson I: Low level of regulatory T cells and maintenance of balance between regulatory T cells and TH17 cells in HIV-1-infected elite controllers. J Acquir Immune Defic Syndr 2011, 57:101-108.
95. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A et al.: Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011, 17:366-371. The authors of this study analysed HIV-1 sequences from newly infected volunteers in the STEP vaccine trial to determine if a 'sieve effect' occurred following vaccination with the MRKAd5 vaccine. The data presented revealed evidence of selective pressure from T cell responses on HIV-1 infection induced by the vaccine.
96. Curlin ME, Cassis-Ghavami F, Magaret AS, Spies GA, Duerr A, Celum CL, Sanchez JL, Margolick JB, Detels R, McElrath MJ, Corey L: Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: A case-control study. AIDS 2011, 25:153-158.
97. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN: Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (step study). J Infect Dis 2012, 206:258-266.
98. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne- Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T et al.: Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.